Welcome to our dedicated page for Pennant Group SEC filings (Ticker: PNTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pennant Group, Inc. filings document the public reporting of a healthcare services holding company with operating subsidiaries in home health, hospice, home care and senior living. Recent Form 8-K reports furnish quarterly and annual results, Regulation FD investor materials, material agreements and amendments tied to acquisitions and financing arrangements.
Proxy filings cover governance, board matters, executive compensation and shareholder voting items. Other material-event amendments provide acquisition-related financial statements and pro forma information, while credit agreement disclosures describe term loans, leverage and coverage covenants, restrictions on indebtedness, liens, dispositions and restricted payments, and healthcare-law-related default provisions.
Pennant Group, Inc. executive Kirk Sterling Cheney, EVP, General Counsel and Corporate Secretary, reported equity compensation awards. He received 4,085 shares of common stock at no cost, which vest immediately on March 3, 2026, bringing his direct holdings to 21,005 shares.
He was also granted a stock option for 30,000 shares of common stock at an exercise price of $33.30 per share. This option begins vesting in five equal annual installments starting on March 5, 2027 and expires on March 5, 2036, representing a long-term incentive award.
Pennant Group Chief Operating Officer John J. Gochnour received new equity awards. On March 3, 2026, he acquired 18,565 shares of common stock as a grant at no cost, bringing his direct common stock holdings to 152,815 shares. On March 5, 2026, he was granted options to buy 41,000 shares of common stock at $33.30 per share, exercisable until March 5, 2036. The 18,565-share grant vests immediately on March 3, 2026, while the 41,000 stock options vest in five equal annual installments beginning March 5, 2027.
Pennant Group, Inc. reported that Chief Financial Officer Lynette Walbom received new equity awards. On March 5, 2026, she was granted stock options covering 34,000 shares of common stock at an exercise price of $33.30 per share, vesting in five equal annual installments beginning March 5, 2027. On March 3, 2026, she also received a grant of 14,292 shares of common stock at no cost, which vest immediately on that date, bringing her directly held common shares to 16,955 after the award.
Pennant Group, Inc. reported a Form 4 showing its Chief Clinical Officer, Jason Paul Steik, received a grant of stock options for 26,000 shares of common stock at an exercise price of $33.30 per share. These options vest in five equal annual installments beginning on March 5, 2027, and represent his full reported option holdings of 26,000 shares following this award.
Pennant Group, Inc. Chief Executive Officer Brent Guerisoli reported equity awards rather than open-market trades. He received a grant of 20,052 shares of common stock that vest immediately on March 3, 2026, increasing his direct common stock holdings to 102,030 shares.
He was also granted a stock option for 45,000 shares of common stock at an exercise price of $33.30 per share. This option vests in five equal annual installments beginning March 5, 2027 and expires on March 5, 2036. Both transactions are classified as grant or award acquisitions, reflecting compensation rather than open-market buying.
The Pennant Group, Inc. files its annual report describing a multi-state healthcare platform focused on home health, hospice and senior living services. As of December 31, 2025, it operated 172 home health and hospice agencies and 63 senior living communities with 4,428 units across 16 states.
Pennant highlights a deliberately decentralized operating model that empowers local leaders, supported by a centralized Service Center for functions like accounting, IT and compliance. From 2016 to 2025, combined home health, hospice and senior living revenue grew 336.3%, a 15.9% compounded annual growth rate, alongside substantial expansion in agency and unit counts.
Revenue is diversified by payor: for 2025, 48.4% came from Medicare, 13.1% from Medicaid, 15.0% from managed care and 23.5% from private and other payors. The home health and hospice segment generated 77.3% of total revenue, with senior living contributing 22.7%. Management emphasizes organic growth, disciplined acquisitions, and strong clinical quality scores, while warning that reimbursement and regulatory changes in Medicare, Medicaid and new laws like the OBBBA represent key risks.
The Pennant Group reported strong fourth-quarter and full-year 2025 results, with total revenue of $947.7 million, up 36.3%, and GAAP diluted EPS of $0.84. Adjusted diluted EPS was $1.18, reflecting acquisitions and operating improvements.
Fourth-quarter revenue reached $289.3 million, up 53.2%, and GAAP diluted EPS was $0.24 with adjusted EPS of $0.34. Home health and hospice revenue grew 41.0% for the year, while senior living revenue rose 22.3%.
For 2026, management guides to revenue between $1,133.6 million and $1,171.8 million, adjusted diluted EPS of $1.26–$1.36, and adjusted EBITDA of $88.5–$94.1 million, incorporating contributions from recently acquired UnitedHealth and Amedisys assets.
The Pennant Group, Inc. received an amended Schedule 13G/A showing that investment entities affiliated with 8 Knots Management and Scott Green together beneficially own 8,705 shares of Pennant common stock, or about 0.03% of the company’s 34,593,720 shares outstanding, based on the issuer’s latest Form 10-Q.
The shares are held through 8 Knots Fund, 8 Knots Fund II, a sub-advised fund, and six separately managed accounts, with 8 Knots Management and Scott Green having varying degrees of investment discretion. The filing states the securities are held in the ordinary course of business and not for the purpose of influencing control.
Pennant Group director reports stock grant. Director Scott E. Lamb reported receiving 2,400 shares of Pennant Group, Inc. common stock on January 15, 2026, coded as an "A" transaction, which typically indicates an award or grant. The shares were granted at a price of $0 per share, increasing his directly held beneficial ownership to 54,135 shares.
According to the footnote, these 2,400 shares vest in three annual installments beginning on January 15, 2027. This means the award is subject to a multi-year vesting schedule, aligning ownership with continued service over time.
Pennant Group director Suzanne D. Snapper reported receiving a grant of 1,900 shares of common stock of Pennant Group, Inc. on January 15, 2026. The shares were acquired at a reported price of $0 per share, indicating an equity award rather than an open-market purchase. After this grant, she beneficially owns 226,564 shares of Pennant Group common stock in total.
According to the footnote, these 1,900 shares vest in three annual installments beginning January 15, 2027, meaning the director will earn the shares over time as vesting conditions are met. The filing classifies her relationship to the company as a director, and the ownership of the reported shares is listed as direct.